Compounds > nvp-cgm097
Page last updated: 2024-11-13

nvp-cgm097

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

NVP-CGM097: an MDM2 and HDM2 inhibitor; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID53240420
CHEMBL ID3601398
SCHEMBL ID2391192
SCHEMBL ID2391196
SCHEMBL ID18458199
MeSH IDM000611625

Synonyms (48)

Synonym
S7875
1313363-54-0
cgm-097
CS-3138
nvp-cgm097
HY-15954
SCHEMBL2391192
SCHEMBL2391196
4t4 ,
(s)-1-(4-chlorophenyl)-7-isopropoxy-6-methoxy-2-(4-(methyl(((1r,4s)-4-(4-methyl-3-oxopiperazin-1-yl)cyclohexyl)methyl)amino)phenyl)-1,2-dihydroisoquinolin-3(4h)-one
AC-32967
nvp-cgm-097
cgm 097
CHEMBL3601398
cgm097
bdbm162123
us9051279, 106
EX-A1059
AKOS030526402
(1s)-1-(4-chlorophenyl)-1,4-dihydro-6-methoxy-7-(1-methylethoxy)-2-[4-[methyl[[trans-4-(4-methyl-3-oxo-1-piperazinyl)cyclohexyl]methyl]amino]phenyl]-3(2h)-isoquinolinone
mfcd28144684
NCGC00390552-01
SCHEMBL18458199
unii-4uf6msl0zh
nvp-cgm097 (cgm-097)
3(2h)-isoquinolinone, 1-(4-chlorophenyl)-1,4-dihydro-6-methoxy-7-(1-methylethoxy)-2-(4-(methyl((trans-4-(4-methyl-3-oxo-1-piperazinyl)cyclohexyl)methyl)amino)phenyl)-, (1s)-
4UF6MSL0ZH ,
(1s)-1-(4-chlorophenyl)-1,4-dihydro-6-methoxy-7-(1-methylethoxy)-2-(4-(methyl((trans-4-(4-methyl-3-oxo-1-piperazinyl)cyclohexyl)methyl)amino)phenyl)-3(2h)-isoquinolinone
cgm 097 [who-dd]
(s)-1-(4-chlorophenyl)-7-isopropoxy-6-methoxy-2-(4-(methyl(((1r,4s)-4-(4-methyl-3-oxopiperazin-1-yl)cyclohexyl)methyl)amino)phenyl)-1,4-dihydroisoquinolin-3(2h)-one
(1s)-1-(4-chlorophenyl)-6-methoxy-2-[4-(methyl{[trans-4-(4-methyl-3-oxopiperazin-1-yl)cyclohexyl]methyl}amino)phenyl]-7-(propan-2-yloxy)-1,4-dihydroisoquinolin-3(2h)-one
BCP18308
nvp cgm097
AS-75288
(1s)-1-(4-chlorophenyl)-6-methoxy-2-{4-[methyl({[(1r,4r)-4-(4-methyl-3-oxopiperazin-1-yl)cyclohexyl]methyl})amino]phenyl}-7-(propan-2-yloxy)-1,2,3,4-tetrahydroisoquinolin-3-one
CCG-270337
(s)-1-(4-chlorophenyl)-7-isopropoxy-6-methoxy-2-(4-[methyl[4-(4-methyl-3-oxopiperazin-1-yl)-trans-cyclohexylmethyl]amino]phenyl)-1,4-dihydro-2h-isoquinolin-3-one
Q27454942
F85069
(1s)-1-(4-chlorophenyl)-6-methoxy-2-[4-[methyl-[[4-(4-methyl-3-oxopiperazin-1-yl)cyclohexyl]methyl]amino]phenyl]-7-propan-2-yloxy-1,4-dihydroisoquinolin-3-one
cgm097cgm097
nsc783015
nsc-783015
cgm097 stereoisomer;(r)-nvp-cgm097
cgm097 dihydrochloride
(s)-1-(4-chlorophenyl)-7-isopropoxy-6-methoxy-2-(4-(methyl(((1r,4r)-4-(4-methyl-3-oxopiperazin-1-yl)cyclohexyl)methyl)amino)phenyl)-1,2-dihydroisoquinolin-3(4h)-one dihydrochloride
nvp-cgm097 dihydrochloride
(s)-1-(4-chlorophenyl)-7-isopropoxy-6-methoxy-2-(4-(methyl(((1r,4r)-4-(4-methyl-3-oxopiperazin-1-yl)cyclohexyl)methyl)amino)phenyl)-1,2-dihydroisoquinolin-3(4h)-one

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
"We used the MDM2 inhibitor NVP-CGM097 to treat in vitro and in vivo models alone and in combination with fulvestrant or palbociclib."( MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer.
Alexandrou, S; Caldon, CE; Chia, KM; Coulson, R; Fernandez, KJ; Halilovic, E; Haupt, S; Haupt, Y; Lim, E; Milioli, HH; Parker, A; Portman, N; Segara, D; Swarbrick, A; Tilley, WD; Yong, A, 2020)		0.86
"We conclude that MDM2 inhibitors in combination with ER degraders or CDK4/6 inhibitors represent a rational strategy for treating advanced, endocrine-resistant ER-positive breast cancer, operating through synergistic activation of cell cycle co-regulatory programmes."( MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer.
Alexandrou, S; Caldon, CE; Chia, KM; Coulson, R; Fernandez, KJ; Halilovic, E; Haupt, S; Haupt, Y; Lim, E; Milioli, HH; Parker, A; Portman, N; Segara, D; Swarbrick, A; Tilley, WD; Yong, A, 2020)		0.56
" MYC/MYCN and MDM2 have been shown to interact and contribute to NB growth and disease progression."( The MDM2 inhibitor CGM097 combined with the BET inhibitor OTX015 induces cell death and inhibits tumor growth in models of neuroblastoma.
Bond, J; Goodyke, A; Kelly, S; Maser, T; Nagulapally, A; Ostrander, A; Park, Y; Saulnier Sholler, G; Zagorski, J, 2020)		0.56

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)		0.51

Dosage Studied

ExcerptRelevanceReference
" Preclinical in vivo studies support clinical exploration while providing preliminary evidence for dosing regimens."( Pharmacokinetic-pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studies.
Bauer, S; Cassier, PA; Demetri, GD; Dummer, R; Fabre, C; Ferretti, S; Guerreiro, N; Halilovic, E; Hourcade-Potelleret, F; Jeay, S; Jullion, A; Meille, C; Tan, DSW; Van Bree, L; Wuerthner, JU, 2021)		0.62
" This study provided insights on dosing optimisation for next-generation HDM2 inhibitors."( Pharmacokinetic-pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studies.
Bauer, S; Cassier, PA; Demetri, GD; Dummer, R; Fabre, C; Ferretti, S; Guerreiro, N; Halilovic, E; Hourcade-Potelleret, F; Jeay, S; Jullion, A; Meille, C; Tan, DSW; Van Bree, L; Wuerthner, JU, 2021)		0.62
" While CGM097 had shown limited activity, with disease control rate of 39% and only one patient in partial response, the preliminary data from the first-in-human escalation study together with the PK/PD modeling provide important insights on how to optimize dosing of next generation HDM2 inhibitors to mitigate hematologic toxicity."( Pharmacokinetic-pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studies.
Bauer, S; Cassier, PA; Demetri, GD; Dummer, R; Fabre, C; Ferretti, S; Guerreiro, N; Halilovic, E; Hourcade-Potelleret, F; Jeay, S; Jullion, A; Meille, C; Tan, DSW; Van Bree, L; Wuerthner, JU, 2021)		0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (17)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
PPM1D proteinHomo sapiens (human)Potency32.99930.00529.466132.9993AID1347411
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency4.77240.01237.983543.2770AID1645841
GVesicular stomatitis virusPotency6.74120.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency21.31740.00108.379861.1304AID1645840
Interferon betaHomo sapiens (human)Potency26.43480.00339.158239.8107AID1347411; AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency6.74120.01238.964839.8107AID1645842
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency6.74120.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency6.74120.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Protein Mdm4Homo sapiens (human)IC50 (µMol)2.10000.00933.78498.2000AID1238675; AID1908067
Cellular tumor antigen p53Homo sapiens (human)IC50 (µMol)0.11290.00060.88508.2000AID1238620; AID1238688
Apoptosis regulator Bcl-2Homo sapiens (human)IC50 (µMol)50.00000.00100.57634.3000AID1238680; AID1238681
E3 ubiquitin-protein ligase Mdm2Mus musculus (house mouse)Ki0.06590.01990.04290.0659AID1238646
E3 ubiquitin-protein ligase Mdm2Canis lupus familiaris (dog)Ki0.02050.01050.01550.0205AID1238645
E3 ubiquitin-protein ligase XIAPHomo sapiens (human)IC50 (µMol)50.00000.00750.62274.1000AID1238684
E3 ubiquitin-protein ligase Mdm2Homo sapiens (human)IC50 (µMol)2.55690.00060.358210.0000AID1238620; AID1238688; AID1555418; AID1908066
E3 ubiquitin-protein ligase Mdm2Homo sapiens (human)Ki0.00130.00090.19811.2400AID1238644
Induced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)IC50 (µMol)50.00000.00442.923510.0000AID1238682; AID1238683
Baculoviral IAP repeat-containing protein 2Homo sapiens (human)IC50 (µMol)50.00000.00040.31212.7200AID1238685
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
E3 ubiquitin-protein ligase Mdm2Homo sapiens (human)Kd0.00230.00000.25851.0000AID1238676
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (367)

Processvia Protein(s)Taxonomy
heart valve developmentProtein Mdm4Homo sapiens (human)
atrioventricular valve morphogenesisProtein Mdm4Homo sapiens (human)
endocardial cushion morphogenesisProtein Mdm4Homo sapiens (human)
ventricular septum developmentProtein Mdm4Homo sapiens (human)
atrial septum developmentProtein Mdm4Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIProtein Mdm4Homo sapiens (human)
negative regulation of cell population proliferationProtein Mdm4Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorProtein Mdm4Homo sapiens (human)
negative regulation of protein catabolic processProtein Mdm4Homo sapiens (human)
negative regulation of apoptotic processProtein Mdm4Homo sapiens (human)
negative regulation of DNA-templated transcriptionProtein Mdm4Homo sapiens (human)
protein stabilizationProtein Mdm4Homo sapiens (human)
regulation of cell cycleProtein Mdm4Homo sapiens (human)
protein-containing complex assemblyProtein Mdm4Homo sapiens (human)
cellular response to hypoxiaProtein Mdm4Homo sapiens (human)
protein ubiquitinationProtein Mdm4Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
protein polyubiquitinationApoptosis regulator Bcl-2Homo sapiens (human)
apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
extrinsic apoptotic signaling pathway via death domain receptorsApoptosis regulator Bcl-2Homo sapiens (human)
response to xenobiotic stimulusApoptosis regulator Bcl-2Homo sapiens (human)
response to toxic substanceApoptosis regulator Bcl-2Homo sapiens (human)
positive regulation of cell growthApoptosis regulator Bcl-2Homo sapiens (human)
response to cytokineApoptosis regulator Bcl-2Homo sapiens (human)
B cell proliferationApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of neuron apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
regulation of calcium ion transportApoptosis regulator Bcl-2Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway in absence of ligandApoptosis regulator Bcl-2Homo sapiens (human)
G1/S transition of mitotic cell cycleApoptosis regulator Bcl-2Homo sapiens (human)
ossificationApoptosis regulator Bcl-2Homo sapiens (human)
ovarian follicle developmentApoptosis regulator Bcl-2Homo sapiens (human)
metanephros developmentApoptosis regulator Bcl-2Homo sapiens (human)
branching involved in ureteric bud morphogenesisApoptosis regulator Bcl-2Homo sapiens (human)
behavioral fear responseApoptosis regulator Bcl-2Homo sapiens (human)
B cell homeostasisApoptosis regulator Bcl-2Homo sapiens (human)
B cell apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
release of cytochrome c from mitochondriaApoptosis regulator Bcl-2Homo sapiens (human)
regulation of cell-matrix adhesionApoptosis regulator Bcl-2Homo sapiens (human)
lymphoid progenitor cell differentiationApoptosis regulator Bcl-2Homo sapiens (human)
B cell lineage commitmentApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of B cell apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
response to ischemiaApoptosis regulator Bcl-2Homo sapiens (human)
renal system processApoptosis regulator Bcl-2Homo sapiens (human)
melanin metabolic processApoptosis regulator Bcl-2Homo sapiens (human)
regulation of nitrogen utilizationApoptosis regulator Bcl-2Homo sapiens (human)
autophagyApoptosis regulator Bcl-2Homo sapiens (human)
humoral immune responseApoptosis regulator Bcl-2Homo sapiens (human)
DNA damage responseApoptosis regulator Bcl-2Homo sapiens (human)
actin filament organizationApoptosis regulator Bcl-2Homo sapiens (human)
axonogenesisApoptosis regulator Bcl-2Homo sapiens (human)
female pregnancyApoptosis regulator Bcl-2Homo sapiens (human)
positive regulation of cell population proliferationApoptosis regulator Bcl-2Homo sapiens (human)
male gonad developmentApoptosis regulator Bcl-2Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to oxidative stressApoptosis regulator Bcl-2Homo sapiens (human)
response to radiationApoptosis regulator Bcl-2Homo sapiens (human)
response to xenobiotic stimulusApoptosis regulator Bcl-2Homo sapiens (human)
response to toxic substanceApoptosis regulator Bcl-2Homo sapiens (human)
post-embryonic developmentApoptosis regulator Bcl-2Homo sapiens (human)
response to iron ionApoptosis regulator Bcl-2Homo sapiens (human)
response to UV-BApoptosis regulator Bcl-2Homo sapiens (human)
response to gamma radiationApoptosis regulator Bcl-2Homo sapiens (human)
regulation of gene expressionApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of autophagyApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of calcium ion transport into cytosolApoptosis regulator Bcl-2Homo sapiens (human)
regulation of glycoprotein biosynthetic processApoptosis regulator Bcl-2Homo sapiens (human)
mesenchymal cell developmentApoptosis regulator Bcl-2Homo sapiens (human)
positive regulation of neuron maturationApoptosis regulator Bcl-2Homo sapiens (human)
smooth muscle cell migrationApoptosis regulator Bcl-2Homo sapiens (human)
positive regulation of smooth muscle cell migrationApoptosis regulator Bcl-2Homo sapiens (human)
cochlear nucleus developmentApoptosis regulator Bcl-2Homo sapiens (human)
gland morphogenesisApoptosis regulator Bcl-2Homo sapiens (human)
regulation of transmembrane transporter activityApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of ossificationApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of cell growthApoptosis regulator Bcl-2Homo sapiens (human)
melanocyte differentiationApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of cell migrationApoptosis regulator Bcl-2Homo sapiens (human)
positive regulation of B cell proliferationApoptosis regulator Bcl-2Homo sapiens (human)
hair follicle morphogenesisApoptosis regulator Bcl-2Homo sapiens (human)
axon regenerationApoptosis regulator Bcl-2Homo sapiens (human)
regulation of protein stabilityApoptosis regulator Bcl-2Homo sapiens (human)
endoplasmic reticulum calcium ion homeostasisApoptosis regulator Bcl-2Homo sapiens (human)
glomerulus developmentApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of cellular pH reductionApoptosis regulator Bcl-2Homo sapiens (human)
regulation of protein localizationApoptosis regulator Bcl-2Homo sapiens (human)
myeloid cell apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of myeloid cell apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
T cell differentiation in thymusApoptosis regulator Bcl-2Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylationApoptosis regulator Bcl-2Homo sapiens (human)
osteoblast proliferationApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of osteoblast proliferationApoptosis regulator Bcl-2Homo sapiens (human)
response to nicotineApoptosis regulator Bcl-2Homo sapiens (human)
organ growthApoptosis regulator Bcl-2Homo sapiens (human)
positive regulation of multicellular organism growthApoptosis regulator Bcl-2Homo sapiens (human)
cellular response to glucose starvationApoptosis regulator Bcl-2Homo sapiens (human)
response to hydrogen peroxideApoptosis regulator Bcl-2Homo sapiens (human)
neuron maturationApoptosis regulator Bcl-2Homo sapiens (human)
T cell homeostasisApoptosis regulator Bcl-2Homo sapiens (human)
positive regulation of apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
CD8-positive, alpha-beta T cell lineage commitmentApoptosis regulator Bcl-2Homo sapiens (human)
ear developmentApoptosis regulator Bcl-2Homo sapiens (human)
regulation of viral genome replicationApoptosis regulator Bcl-2Homo sapiens (human)
positive regulation of melanocyte differentiationApoptosis regulator Bcl-2Homo sapiens (human)
retinal cell programmed cell deathApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of retinal cell programmed cell deathApoptosis regulator Bcl-2Homo sapiens (human)
regulation of mitochondrial membrane permeabilityApoptosis regulator Bcl-2Homo sapiens (human)
focal adhesion assemblyApoptosis regulator Bcl-2Homo sapiens (human)
spleen developmentApoptosis regulator Bcl-2Homo sapiens (human)
thymus developmentApoptosis regulator Bcl-2Homo sapiens (human)
digestive tract morphogenesisApoptosis regulator Bcl-2Homo sapiens (human)
oocyte developmentApoptosis regulator Bcl-2Homo sapiens (human)
skeletal muscle fiber developmentApoptosis regulator Bcl-2Homo sapiens (human)
positive regulation of skeletal muscle fiber developmentApoptosis regulator Bcl-2Homo sapiens (human)
pigment granule organizationApoptosis regulator Bcl-2Homo sapiens (human)
stem cell developmentApoptosis regulator Bcl-2Homo sapiens (human)
homeostasis of number of cells within a tissueApoptosis regulator Bcl-2Homo sapiens (human)
B cell receptor signaling pathwayApoptosis regulator Bcl-2Homo sapiens (human)
response to glucocorticoidApoptosis regulator Bcl-2Homo sapiens (human)
neuron apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
defense response to virusApoptosis regulator Bcl-2Homo sapiens (human)
establishment of localization in cellApoptosis regulator Bcl-2Homo sapiens (human)
regulation of mitochondrial membrane potentialApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of mitochondrial depolarizationApoptosis regulator Bcl-2Homo sapiens (human)
hematopoietic stem cell differentiationApoptosis regulator Bcl-2Homo sapiens (human)
calcium ion transport into cytosolApoptosis regulator Bcl-2Homo sapiens (human)
T cell apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of T cell apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
cellular response to organic substanceApoptosis regulator Bcl-2Homo sapiens (human)
cellular response to hypoxiaApoptosis regulator Bcl-2Homo sapiens (human)
reactive oxygen species metabolic processApoptosis regulator Bcl-2Homo sapiens (human)
dendritic cell apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
motor neuron apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
cell-cell adhesionApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorApoptosis regulator Bcl-2Homo sapiens (human)
epithelial cell apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of epithelial cell apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of G1/S transition of mitotic cell cycleApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of dendritic cell apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of motor neuron apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of anoikisApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of apoptotic signaling pathwayApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathwayApoptosis regulator Bcl-2Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damageApoptosis regulator Bcl-2Homo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligandApoptosis regulator Bcl-2Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
apoptotic processE3 ubiquitin-protein ligase Mdm2Canis lupus familiaris (dog)
protein ubiquitinationE3 ubiquitin-protein ligase Mdm2Canis lupus familiaris (dog)
regulation of cell cycleE3 ubiquitin-protein ligase Mdm2Canis lupus familiaris (dog)
regulation of biological qualityE3 ubiquitin-protein ligase Mdm2Canis lupus familiaris (dog)
regulation of apoptotic processE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
DNA damage responseE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
negative regulation of tumor necrosis factor-mediated signaling pathwayE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
Wnt signaling pathwayE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
regulation of BMP signaling pathwayE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
positive regulation of protein ubiquitinationE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
positive regulation of type I interferon productionE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
regulation of cell population proliferationE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
defense response to bacteriumE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
negative regulation of apoptotic processE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
regulation of innate immune responseE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
positive regulation of JNK cascadeE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
regulation of inflammatory responseE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
neuron apoptotic processE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
copper ion homeostasisE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
regulation of apoptosis involved in tissue homeostasisE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
regulation of nucleotide-binding domain, leucine rich repeat containing receptor signaling pathwayE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
nucleotide-binding oligomerization domain containing 1 signaling pathwayE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
nucleotide-binding oligomerization domain containing 2 signaling pathwayE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
protein K63-linked ubiquitinationE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
positive regulation of canonical Wnt signaling pathwayE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
inhibition of cysteine-type endopeptidase activityE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
positive regulation of protein linear polyubiquitinationE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
regulation of cell cycleE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
regulation of cell cycleE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
ubiquitin-dependent protein catabolic processE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
protein polyubiquitinationE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
blood vessel developmentE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
blood vessel remodelingE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
regulation of heart rateE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
atrioventricular valve morphogenesisE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
endocardial cushion morphogenesisE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
ventricular septum developmentE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
atrial septum developmentE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
ubiquitin-dependent protein catabolic processE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
apoptotic processE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
traversing start control point of mitotic cell cycleE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
positive regulation of cell population proliferationE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
response to xenobiotic stimulusE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
response to toxic substanceE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
response to iron ionE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
positive regulation of gene expressionE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
negative regulation of protein processingE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
negative regulation of neuron projection developmentE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
protein ubiquitinationE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
protein sumoylationE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
protein destabilizationE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
response to magnesium ionE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
protein localization to nucleusE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
regulation of protein catabolic processE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
response to cocaineE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
negative regulation of DNA damage response, signal transduction by p53 class mediatorE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
establishment of protein localizationE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
response to etherE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
negative regulation of DNA-templated transcriptionE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
positive regulation of mitotic cell cycleE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
response to antibioticE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
positive regulation of protein export from nucleusE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
response to steroid hormoneE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
positive regulation of muscle cell differentiationE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
proteolysis involved in protein catabolic processE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
protein autoubiquitinationE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
cardiac septum morphogenesisE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
protein-containing complex assemblyE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
cellular response to hydrogen peroxideE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
cellular response to vitamin B1E3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
cellular response to alkaloidE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
cellular response to growth factor stimulusE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
cellular response to peptide hormone stimulusE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
cellular response to estrogen stimulusE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
cellular response to hypoxiaE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
cellular response to gamma radiationE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
cellular response to UV-CE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
fibroblast activationE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
cellular response to actinomycin DE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
negative regulation of signal transduction by p53 class mediatorE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway by p53 class mediatorE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
response to formaldehydeE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferationE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell migrationE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
amyloid fibril formationE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
response to water-immersion restraint stressE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
negative regulation of apoptotic processE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
cell cycleE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
regulation of gene expressionE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
DNA damage responseInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
response to cytokineInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
cell fate determinationInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
negative regulation of autophagyInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
cellular homeostasisInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
positive regulation of apoptotic processInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
negative regulation of apoptotic processInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
protein transmembrane transportInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligandInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
positive regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathwayInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
negative regulation of anoikisInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway in absence of ligandInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
mitochondrial fusionInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
release of cytochrome c from mitochondriaInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damageInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
protein polyubiquitinationBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
response to hypoxiaBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
placenta developmentBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
apoptotic processBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
cell surface receptor signaling pathwayBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
canonical NF-kappaB signal transductionBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
regulation of toll-like receptor signaling pathwayBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
non-canonical NF-kappaB signal transductionBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
regulation of RIG-I signaling pathwayBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
regulation of cell population proliferationBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
regulation of apoptotic processBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
negative regulation of apoptotic processBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
regulation of innate immune responseBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
response to ethanolBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
regulation of cell differentiationBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
regulation of inflammatory responseBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
response to cAMPBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
regulation of cell cycleBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
regulation of necroptotic processBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
necroptotic processBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
regulation of nucleotide-binding domain, leucine rich repeat containing receptor signaling pathwayBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
regulation of non-canonical NF-kappaB signal transductionBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
negative regulation of ripoptosome assembly involved in necroptotic processBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
positive regulation of protein K63-linked ubiquitinationBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
positive regulation of protein K48-linked ubiquitinationBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
positive regulation of protein monoubiquitinationBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
regulation of cysteine-type endopeptidase activityBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
regulation of reactive oxygen species metabolic processBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
positive regulation of protein ubiquitinationBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
negative regulation of necroptotic processBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (78)

Processvia Protein(s)Taxonomy
protein bindingProtein Mdm4Homo sapiens (human)
zinc ion bindingProtein Mdm4Homo sapiens (human)
enzyme bindingProtein Mdm4Homo sapiens (human)
ubiquitin-protein transferase activityProtein Mdm4Homo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
protease bindingApoptosis regulator Bcl-2Homo sapiens (human)
protein bindingApoptosis regulator Bcl-2Homo sapiens (human)
channel activityApoptosis regulator Bcl-2Homo sapiens (human)
channel inhibitor activityApoptosis regulator Bcl-2Homo sapiens (human)
ubiquitin protein ligase bindingApoptosis regulator Bcl-2Homo sapiens (human)
identical protein bindingApoptosis regulator Bcl-2Homo sapiens (human)
sequence-specific DNA bindingApoptosis regulator Bcl-2Homo sapiens (human)
protein heterodimerization activityApoptosis regulator Bcl-2Homo sapiens (human)
BH3 domain bindingApoptosis regulator Bcl-2Homo sapiens (human)
protein phosphatase 2A bindingApoptosis regulator Bcl-2Homo sapiens (human)
molecular adaptor activityApoptosis regulator Bcl-2Homo sapiens (human)
DNA-binding transcription factor bindingApoptosis regulator Bcl-2Homo sapiens (human)
BH domain bindingApoptosis regulator Bcl-2Homo sapiens (human)
5S rRNA bindingE3 ubiquitin-protein ligase Mdm2Canis lupus familiaris (dog)
identical protein bindingE3 ubiquitin-protein ligase Mdm2Canis lupus familiaris (dog)
ribonucleoprotein complex bindingE3 ubiquitin-protein ligase Mdm2Canis lupus familiaris (dog)
ubiquitin bindingE3 ubiquitin-protein ligase Mdm2Canis lupus familiaris (dog)
metal ion bindingE3 ubiquitin-protein ligase Mdm2Canis lupus familiaris (dog)
ubiquitin-protein transferase activityE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
cysteine-type endopeptidase inhibitor activityE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
protein bindingE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
identical protein bindingE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
cysteine-type endopeptidase inhibitor activity involved in apoptotic processE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
metal ion bindingE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
endopeptidase regulator activityE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
ubiquitin protein ligase activityE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
protein serine/threonine kinase bindingE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
p53 bindingE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
ubiquitin-protein transferase activityE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
protein bindingE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
5S rRNA bindingE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
zinc ion bindingE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
ligase activityE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
SUMO transferase activityE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
enzyme bindingE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
protein domain specific bindingE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
ubiquitin protein ligase bindingE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
receptor serine/threonine kinase bindingE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
identical protein bindingE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
peroxisome proliferator activated receptor bindingE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
ribonucleoprotein complex bindingE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
ubiquitin bindingE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
ubiquitin protein ligase activityE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
NEDD8 ligase activityE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
disordered domain specific bindingE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
protein bindingInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
protein transmembrane transporter activityInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
protein heterodimerization activityInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
BH3 domain bindingInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
channel activityInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
BH domain bindingInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
transcription coactivator activityBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
ubiquitin-protein transferase activityBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
protein bindingBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
zinc ion bindingBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
transferase activityBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
identical protein bindingBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
ubiquitin bindingBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
protein-containing complex bindingBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
protein-folding chaperone bindingBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
FBXO family protein bindingBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
ubiquitin protein ligase activityBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
cysteine-type endopeptidase inhibitor activity involved in apoptotic processBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (47)

Processvia Protein(s)Taxonomy
nucleusProtein Mdm4Homo sapiens (human)
nucleoplasmProtein Mdm4Homo sapiens (human)
transcription repressor complexProtein Mdm4Homo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
mitochondrial outer membraneApoptosis regulator Bcl-2Homo sapiens (human)
endoplasmic reticulum membraneApoptosis regulator Bcl-2Homo sapiens (human)
nucleusApoptosis regulator Bcl-2Homo sapiens (human)
cytoplasmApoptosis regulator Bcl-2Homo sapiens (human)
mitochondrionApoptosis regulator Bcl-2Homo sapiens (human)
mitochondrial outer membraneApoptosis regulator Bcl-2Homo sapiens (human)
endoplasmic reticulumApoptosis regulator Bcl-2Homo sapiens (human)
cytosolApoptosis regulator Bcl-2Homo sapiens (human)
membraneApoptosis regulator Bcl-2Homo sapiens (human)
nuclear membraneApoptosis regulator Bcl-2Homo sapiens (human)
myelin sheathApoptosis regulator Bcl-2Homo sapiens (human)
BAD-BCL-2 complexApoptosis regulator Bcl-2Homo sapiens (human)
protein-containing complexApoptosis regulator Bcl-2Homo sapiens (human)
pore complexApoptosis regulator Bcl-2Homo sapiens (human)
cytosolE3 ubiquitin-protein ligase Mdm2Mus musculus (house mouse)
nucleusE3 ubiquitin-protein ligase Mdm2Canis lupus familiaris (dog)
nucleoplasmE3 ubiquitin-protein ligase Mdm2Canis lupus familiaris (dog)
nucleolusE3 ubiquitin-protein ligase Mdm2Canis lupus familiaris (dog)
cytoplasmE3 ubiquitin-protein ligase Mdm2Canis lupus familiaris (dog)
cytoplasmE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
nucleusE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
nucleoplasmE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
cytoplasmE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
cytosolE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
nucleusE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
nuclear bodyE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
nucleusE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
nucleoplasmE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
nucleolusE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
cytoplasmE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
cytosolE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
plasma membraneE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
transcription repressor complexE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
endocytic vesicle membraneE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
protein-containing complexE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
nucleusInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
nucleoplasmInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
cytoplasmInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
mitochondrionInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
mitochondrial outer membraneInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
cytosolInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
membraneInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
Bcl-2 family protein complexInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
mitochondrial outer membraneInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
XY bodyBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
nucleusBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
cytoplasmBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
cytosolBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
cytoplasmic side of plasma membraneBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
CD40 receptor complexBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
nucleusBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
cytoplasmBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (120)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1238682Inhibition of Mcl1 (unknown origin) assessed as inhibition of Mcl1-Bak interaction by TR-FRET assay2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238734AUC (0 to 24 hrs) in human SJSA1 cells xenografted rat assessed as mouse survival at 20 mg/kg, po qd2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238693Inhibition of cell proliferation of human Saos2 cells deficient with p53 gene2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238690Inhibition of cell proliferation of human HCT116 cells deficient with p53 gene2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238621Inhibition of cell proliferation of human SJSA1 cells2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238706Toxicity in monkey assessed as changes in testes parameters2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238659Clearance in beagle dog at 0.1 mg/kg, iv2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238639AUC in Sprague-Dawley rat at 3 mg/kg, po2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238702Toxicity in human SJSA1 cells xenografted dosed rat assessed as induction of histopathological changes at 30 mg/kg, po qd2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1555418Inhibition of p53 derived Cy5-p53 peptide (18 to 26 residues) binding to human MDM2 (2 to 188 residues) after 30 mins by TR-FRET assay2019European journal of medicinal chemistry, Aug-15, Volume: 176The past, present and future of potential small-molecule drugs targeting p53-MDM2/MDMX for cancer therapy.
AID1238635Clearance in Sprague-Dawley rat at 1 mg/kg, iv2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238680Inhibition of Bcl2 (unknown origin) assessed as inhibition of Bcl2-Bak interaction by TR-FRET assay2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238623Permeability of the compound by PAMPA method2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238653Terminal half life in OF1 mouse at 1 mg/kg, iv2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238729Toxicity in human SJSA1 cells xenografted rat assessed as mouse survival at 30 mg/kg, po qd2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238673Oral bioavailability in cynomolgus monkey at 0.3 mg/kg2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238652Volume of distribution at steady state in OF1 mouse at 1 mg/kg, iv2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238656Tmax in OF1 mouse at 3 mg/kg, po2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238629Octanol water partition coefficient, logP of the compound2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238687Selectivity index, ratio of IC50 for Ras-Raf interaction (unknown origin) to IC50 for MDM2/p53 interaction (unknown origin)2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1908067Inhibition of human MDM4 by TR-FRET assay
AID1238676Inhibition of human MDM2 L33E mutant (14 to 111 residues) by ITC method2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238707Toxicity in rat assessed as changes in testes parameters2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238642Oral bioavailability in Sprague-Dawley rat at 3 mg/kg2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238640Cmax in Sprague-Dawley rat at 3 mg/kg, po2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238648Selectivity index, ratio of Ki for dog MDM2 to Ki for human MDM2 by TR-FRET assay2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238739AUC (0 to 48 hrs) in human SJSA1 cells xenografted rat assessed as mouse survival at 70 mg/kg, po dosed 3 times per week2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238685Inhibition of cIAP (unknown origin) assessed as inhibition of cIAP-BIR3 interaction by TR-FRET assay2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238665Oral bioavailability in beagle dog at 0.3 mg/kg2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238683Inhibition of Mcl1 (unknown origin) assessed as inhibition of Mcl1-Noxa interaction by TR-FRET assay2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238668Volume of distribution at steady state in cynomolgus monkey at 0.1 mg/kg, iv2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238724Toxicity in human SJSA1 cells xenografted rat assessed as change in body weight at 30 mg/kg, po dosed three times per week (Rvb = 1.9 to 6.8%)2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238712Toxicity in rat testes assessed as effect on proliferative cells2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238719Antitumor activity against human SJSA1 cells xenografted in rat assessed as tumor regression at 70 mg/kg, po dosed three times per week2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238649Selectivity index, ratio of Ki for mouse MDM2 to Ki for human MDM2 by TR-FRET assay2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238696In-vivo inhibition of MDM2/p53 interaction in human SJSA1 cells xenografted rat assessed as increase in MDM2 mRNA level at 30 mg/kg, po measured within 72 hrs post dose by qRT-PCR method2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238650Selectivity index, ratio of Ki for rat MDM2 to Ki for human MDM2 by TR-FRET assay2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238681Inhibition of Bcl2 (unknown origin) assessed as inhibition of Bcl2-Bad interaction by TR-FRET assay2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238655Cmax in OF1 mouse at 3 mg/kg, po2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238664Tmax in beagle dog at 0.3 mg/kg, po2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238711Toxicity in rat assessed as induction of structural changes in testes tubular epithelium2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238695In-vivo inhibition of MDM2/p53 interaction in human SJSA1 cells xenografted rat assessed as increase in p21 mRNA level at 30 mg/kg, po measured within 72 hrs post dose by qRT-PCR method2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238637Volume of distribution at steady state in Sprague-Dawley rat at 1 mg/kg, iv2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238671Cmax in cynomolgus monkey at 0.3 mg/kg, po2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238631Intrinsic clearance in human liver microsomes2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238732AUC (0 to 24 hrs) in human SJSA1 cells xenografted rat assessed as mouse survival at 5 mg/kg, po qd2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238645Inhibition of dog MDM2 by TR-FRET assay2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238698Antitumor activity against human SJSA1 cells xenografted in rat assessed as reduction tumor growth dosed orally on daily basis under q24h regime2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238636Terminal half life in Sprague-Dawley rat at 1 mg/kg, iv2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238646Inhibition of mouse MDM2 by TR-FRET assay2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238733AUC (0 to 24 hrs) in human SJSA1 cells xenografted rat assessed as mouse survival at 10 mg/kg, po qd2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238738AUC (0 to 24 hrs) in human SJSA1 cells xenografted rat assessed as mouse survival at 70 mg/kg, po dosed 3 times per week2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238667Clearance in cynomolgus monkey at 0.1 mg/kg, iv2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238670AUC in cynomolgus monkey at 0.3 mg/kg, po2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238641Tmax in Sprague-Dawley rat at 3 mg/kg, po2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238718Antitumor activity against human SJSA1 cells xenografted in rat assessed as tumor regression at 30 mg/kg, po dosed three times per week2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238663Cmax in beagle dog at 0.3 mg/kg, po2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238678Potency index, ratio of IC50 for nutlin-3 to IC50 for test compound against human MDM2 by TR-FRET assay2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238675Inhibition of human MDM4 by TR-FRET assay2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238658Protein binding in OF1 mouse plasma by equilibrium dialysis method2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238684Inhibition of XIAP (unknown origin) assessed as inhibition of XIAP-BIR3 interaction by TR-FRET assay2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238737AUC (0 to 48 hrs) in human SJSA1 cells xenografted rat assessed as mouse survival at 30 mg/kg, po dosed 3 times per week2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238677Binding affinity to human MDM2 assessed as change in melting temperature by DSF method2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238703Toxicity in monkey assessed as changes in bone marrow parameters2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238692Inhibition of cell proliferation of human SJSA1 cells expressing p532015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238628Time dependent inhibition of CYP3A4 in human liver microsomes2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238630Intrinsic clearance in monkey liver microsomes2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238715Antitumor activity against human SJSA1 cells xenografted in rat assessed as effect on tumor growth at 10 mg/kg, po qd2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238647Inhibition of rat MDM2 by TR-FRET assay2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238662AUC in beagle dog at 0.3 mg/kg, po2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238713Toxicity in monkey testes assessed as effect on germinal cells2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238735AUC (0 to 24 hrs) in human SJSA1 cells xenografted rat assessed as mouse survival at 30 mg/kg, po qd2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238721Toxicity in human SJSA1 cells xenografted rat assessed as change in body weight at 10 mg/kg, po qd (Rvb = 1.9 to 6.8%)2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238704Toxicity in monkey assessed as changes in lymphoid organs parameters2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238705Toxicity in monkey assessed as changes in GI tract parameters2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238686Selectivity index, ratio of IC50 for p53-MDM4 (unknown origin) interaction to IC50 for MDM2/p53 interaction (unknown origin)2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238730Toxicity in human SJSA1 cells xenografted rat assessed as mouse survival at 30 mg/kg, po dosed 3 times per week2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238727Toxicity in human SJSA1 cells xenografted rat assessed as mouse survival at 10 mg/kg, po qd2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238714Antitumor activity against human SJSA1 cells xenografted in rat assessed as effect on tumor growth at 5 mg/kg, po qd2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238691Selectivity index, ratio of IC50 for inhibition of cell proliferation of human HCT116 cells deficient with p53 gene to IC50 for inhibition of cell proliferation of human HCT116 cells expressing p532015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238722Toxicity in human SJSA1 cells xenografted rat assessed as change in body weight at 20 mg/kg, po qd (Rvb = 1.9 to 6.8%)2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238657Oral bioavailability in OF1 mouse at 3 mg/kg2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238689Inhibition of cell proliferation of human HCT116 cells expressing p532015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238669Terminal half life in in cynomolgus monkey at 0.1 mg/kg, iv2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238716Antitumor activity against human SJSA1 cells xenografted in rat assessed as effect on tumor growth at 20 mg/kg, po qd2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238694Selectivity index, ratio of IC50 for inhibition of cell proliferation of human Saos2 cells deficient with p53 gene to IC50 for inhibition of cell proliferation of human SJSA1 cells expressing p532015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238726Toxicity in human SJSA1 cells xenografted rat assessed as mouse survival at 5 mg/kg, po qd2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238699Antitumor activity against human SJSA1 cells xenografted in rat assessed as reduction tumor growth dosed orally three times per week2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238725Toxicity in human SJSA1 cells xenografted rat assessed as change in body weight at 70 mg/kg, po dosed three times per week (Rvb = 1.9 to 6.8%)2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1908066Inhibition of human MDM2 by TR-FRET assay
AID1238654AUC in OF1 mouse at 3 mg/kg, po2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238688Inhibition of MDM2/p53 interaction (unknown origin) assessed as p53 nuclear translocation by GRIP p53 translocation assay2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238736AUC (0 to 24 hrs) in human SJSA1 cells xenografted rat assessed as mouse survival at 30 mg/kg, po dosed 3 times per week2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238708Toxicity in rat assessed as changes in heart parameters2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238660Volume of distribution at steady state in beagle dog at 0.1 mg/kg, iv2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238666Protein binding in beagle dog plasma by equilibrium dialysis method2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238717Antitumor activity against human SJSA1 cells xenografted in rat assessed as tumor regression at 30 mg/kg, po qd2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238661Terminal half life in beagle dog at 0.1 mg/kg, iv2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238643Protein binding in Sprague-Dawley rat plasma by equilibrium dialysis method2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238720Toxicity in human SJSA1 cells xenografted rat assessed as change in body weight at 5 mg/kg, po qd (Rvb = 1.9 to 6.8%)2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238651Clearance in OF1 mouse at 1 mg/kg, iv2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238710Toxicity in female rat assessed as changes in adrenal gland parameters2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238731Toxicity in human SJSA1 cells xenografted rat assessed as mouse survival at 70 mg/kg, po dosed 3 times per week2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238728Toxicity in human SJSA1 cells xenografted rat assessed as mouse survival at 20 mg/kg, po qd2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238674Protein binding in cynomolgus monkey plasma by equilibrium dialysis method2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238620Inhibition of MDM2/p53 interaction (unknown origin) using biotinylated MDM2 and Cy5-p53 (18 to 26 amino acids) by TR-FRET assay2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238723Toxicity in human SJSA1 cells xenografted rat assessed as change in body weight at 30 mg/kg, po qd (Rvb = 1.9 to 6.8%)2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238709Toxicity in male rat assessed as changes in adrenal gland parameters2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238679Inhibition of Ras (unknown origin) assessed as inhibition of Ras-Raf interaction by TR-FRET assay2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238672Tmax in cynomolgus monkey at 0.3 mg/kg, po2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238701Toxicity in human SJSA1 cells xenografted dosed rat assessed as drug toleration dosed orally on daily basis under q24h regime2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238644Inhibition of human MDM2 by TR-FRET assay2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238700Toxicity in human SJSA1 cells xenografted dosed rat assessed as induction of histopathological changes dosed orally on daily basis under q24h regime2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1238697In-vivo inhibition of MDM2/p53 interaction in human SJSA1 cells xenografted rat assessed as increase in PUMA mRNA level at 30 mg/kg, po measured within 72 hrs post dose by qRT-PCR method2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's8 (53.33)24.3611
2020's7 (46.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 28.32

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index28.32 (24.57)
Research Supply Index2.83 (2.92)
Research Growth Index4.53 (4.65)
Search Engine Demand Index22.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (28.32)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (6.67%)5.53%
Reviews1 (6.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (86.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
fluorouracil
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.		7.1710nucleobase analogue;
organofluorine compound		antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic
pyrroles
1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.		2.1310pyrrole;
secondary amine
quinazolines
Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.		2.1310azaarene;
mancude organic heterobicyclic parent;
ortho-fused heteroarene;
quinazolines
fulvestrant
Fulvestrant: An estradiol derivative and estrogen receptor antagonist that is used for the treatment of estrogen receptor-positive, locally advanced or metastatic breast cancer.. fulvestrant : A 3-hydroxy steroid that is 17beta-estradiol in which the 7alpha hydrogen has been replaced by a nonyl group in which one of the hydrogens of the terminal methyl has been replaced by a (4,4,5,5,5-pentafluoropentyl)sulfinyl group. An estrogen receptor antagonist, it is used in the treatment of breast cancer.		2.251017beta-hydroxy steroid;
3-hydroxy steroid;
organofluorine compound;
sulfoxide		antineoplastic agent;
estrogen antagonist;
estrogen receptor antagonist
nutlin 3
[no description available]		3.3110stilbenoid
palbociclib
[no description available]		2.2510aminopyridine;
aromatic ketone;
cyclopentanes;
piperidines;
pyridopyrimidine;
secondary amino compound;
tertiary amino compound		antineoplastic agent;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
everolimus
[no description available]		2.1310cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
primary alcohol;
secondary alcohol		anticoronaviral agent;
antineoplastic agent;
geroprotector;
immunosuppressive agent;
mTOR inhibitor
staurosporine
staurosporinium : Conjugate acid of staurosporine.		2.1110ammonium ion derivative
midostaurin
midostaurin : An organic heterooctacyclic compound that is the N-benzoyl derivative of staurosporine.		2.1110benzamides;
gamma-lactam;
indolocarbazole;
organic heterooctacyclic compound		antineoplastic agent;
EC 2.7.11.13 (protein kinase C) inhibitor
6h-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, 4-(4-chlorophenyl)-n-(4-hydroxyphenyl)-2,3,9-trimethyl-, (6s)-
[no description available]		2.2510organonitrogen heterocyclic compound;
organosulfur heterocyclic compound
sotrastaurin
sotrastaurin: a potent protein kinase C-selective inhibitor; structure in first source. sotrastaurin : A member of the class of maleimides that is maleimide which is substituted at position 3 by an indol-3-yl group and at position 4 by a quinazolin-4-yl group, which in turn is substituted at position 2 by a 4-methylpiperazin-1-yl group. It is a potent and selective inhibitor of protein kinase C and has been investigated as an immunosuppresant in renal transplant patients.		2.1310indoles;
maleimides;
N-alkylpiperazine;
N-arylpiperazine;
quinazolines		anticoronaviral agent;
EC 2.7.11.13 (protein kinase C) inhibitor;
immunosuppressive agent
nutlin-3a
nutlin 3: an MDM2 antagonist; structure in first source		3.6520stilbenoid
quizartinib
[no description available]		2.1110benzoimidazothiazole;
isoxazoles;
morpholines;
phenylureas		antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
necroptosis inhibitor
ConditionIndicatedRelationship StrengthStudiesTrials
Congenital Zika Syndrome
[description not available]		02.2510
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.2510
Zika Virus Infection
A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.		02.2510
Breast Cancer
[description not available]		02.2510
Breast Neoplasms
Tumors or cancer of the human BREAST.		02.2510
Neuroblastoma
A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)		02.2510
Benign Neoplasms
[description not available]		04.8821
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		04.8821
Acute Myelogenous Leukemia
[description not available]		02.1110
Leukemia, Myeloid, Acute
Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.		02.1110
Leucocythaemia
[description not available]		02.1310
Experimental Leukemia
[description not available]		02.1310
Germinoblastoma
[description not available]		02.1310
Leukemia, Pre-B-Cell
[description not available]		02.1310
Leukemia
A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)		02.1310
Lymphoma
A general term for various neoplastic diseases of the lymphoid tissue.		02.1310
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
A leukemia/lymphoma found predominately in children and adolescents and characterized by a high number of lymphoblasts and solid tumor lesions. Frequent sites involve LYMPH NODES, skin, and bones. It most commonly presents as leukemia.		02.1310
Malignant Melanoma
[description not available]		02.1310
Melanoma
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)		02.1310
Uveal Neoplasms
Tumors or cancer of the UVEA.		02.1310
Neuroendocrine Tumors
Tumors whose cells possess secretory granules and originate from the neuroectoderm, i.e., the cells of the ectoblast or epiblast that program the neuroendocrine system. Common properties across most neuroendocrine tumors include ectopic hormone production (often via APUD CELLS), the presence of tumor-associated antigens, and isozyme composition.		02.1710